Using 18F-PFPN PET imaging to diagnose and stage clear cell sarcoma of soft tissue
Clinical Application of 18F-PFPN PET Imaging in Diagnosis and Staging of Clear Cell Sarcoma of Soft Tissue
NA · Wuhan Union Hospital, China · NCT05963035
This study is testing a new type of PET imaging to see if it can better diagnose and stage clear cell sarcoma in patients with this rare cancer.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Wuhan Union Hospital, China (other) |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT05963035 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of 18F-PFPN PET imaging in diagnosing and staging clear cell sarcoma of soft tissue, a rare malignancy. Patients with suspected or confirmed cases will undergo both 18F-PFPN PET/MR imaging and 18F-FDG PET imaging to compare their diagnostic efficacy. The study aims to collect clinical data, imaging results, and histopathology to assess the performance of 18F-PFPN in detecting melanin-containing lesions. A total of 10 cases will be included in this prospective monocentric study.
Who should consider this trial
Good fit: Ideal candidates are adult patients aged 18 and above with clinically suspected or confirmed clear cell sarcoma of soft tissue.
Not a fit: Patients with acute systemic diseases, those who are pregnant or breastfeeding, or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of diagnosing and staging clear cell sarcoma of soft tissue, leading to better treatment outcomes.
How similar studies have performed: While the use of 18F-PFPN PET imaging is novel, similar imaging approaches have shown promise in other malignancies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (age 18 years or above), regardless of gender; * Patients with clinically suspected or confirmed clear cell sarcoma of soft tissue (supporting evidence including visual examination, MRI, CT, ultrasound, and histopathological examination, etc.) ; * Patients who agree to undergo both 18F-PFPN and 18F-FDG PET imaging. Exclusion Criteria: * Acute systemic diseases and electrolyte disturbances; * Patients who plan to get pregnant within six months or are pregnant or breastfeeding; * The patient or his/her legal representative is unable or unwilling to sign the informed consent.
Where this trial is running
Wuhan, Hubei
- China, Hubei Province — Wuhan, Hubei, China (RECRUITING)
Study contacts
- Study coordinator: Xiaoli Lan
- Email: lxl730724@hotmail.com
- Phone: 0086-027-83692633
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Clear Cell Sarcoma of Soft Tissue